Patents Represented by Attorney, Agent or Law Firm Dale L. Rieger
-
Patent number: 6828435Abstract: The use of protection schemes and solid phase synthesis reactions to generate molecules of core structure M, which have a plurality of moieties, each of which can be individually deprotected or subsequently derivatized are provided. In one process, M is a multifunctional low molecular weight compound, such as a saccharide, aminosugar, deoxysugar, nucleoside, nucleotide, coenzyme, amino acid, lipid, steroid, vitamin, hormone, alkaloid, or small molecule drug. In another process, M is an oligomeric compound, such as an oligosaccharide, oligonucleotide, peptide or protein.Type: GrantFiled: July 2, 1999Date of Patent: December 7, 2004Assignee: HK Pharmaceuticals, Inc.Inventors: Hubert Koster, Eckart Leikauf
-
Patent number: 6790458Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: April 7, 2003Date of Patent: September 14, 2004Assignee: AP Pharma Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller
-
Patent number: 6774277Abstract: Methods of treatment of cyanide-containing waste are provided. In particular, methods for treatment of spent potliner prior to landfill disposal are provided. These methods, which involve treatment of the waste with a mixture containing an aqueous oxidizing solution containing an agent, such as a metal chloride, that increases the oxidation potential of the solution, can be performed at ambient temperature and pressure.Type: GrantFiled: March 7, 2000Date of Patent: August 10, 2004Assignee: Waste Management, Inc.Inventor: Gary Fisher
-
Patent number: 6696473Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.Type: GrantFiled: December 20, 2002Date of Patent: February 24, 2004Assignee: X-Ceptor Therapeutics, Inc.Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
-
Patent number: 6686382Abstract: Thienyl-, furyl-, pyrrolyl- and phenylsulfonamides, formulations of pharmaceutically-acceptable derivatives thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, N-(isoxazolyl)pyrrolylsulfonamides and N-(isoxazolyl)phenylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or pharmaceutically acceptable derivatives thereof that inhibit the activity of endothelin are also provided.Type: GrantFiled: December 29, 2000Date of Patent: February 3, 2004Assignee: Encysive Pharmaceuticals Inc.Inventors: Chengde Wu, Natalie Blok, George W. Holland
-
Patent number: 6683103Abstract: Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.Type: GrantFiled: December 20, 2001Date of Patent: January 27, 2004Assignee: Texas Biotechnology CorporationInventors: Chengde Wu, Natalie Blok, Timothy Kogan, Karin Keller
-
Patent number: 6632829Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.Type: GrantFiled: November 5, 2001Date of Patent: October 14, 2003Assignee: Texas Biotechnology Corp.Inventors: Chengde Wu, Bore Gowda Raju, Timothy Kogan, Natalie Blok, Patricia Woodard
-
Patent number: 6613804Abstract: Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: December 4, 2001Date of Patent: September 2, 2003Assignee: Encysive Pharmaceuticals, Inc.Inventors: Ming Fai Chan, Timothy Kogan, Erik Joel Verner, Adam Kois, Vitukudi Narayanaiyengar Balaji
-
Patent number: 6596916Abstract: Methods of treatment of cyanide-containing waste are provided. In particular, methods for treatment of spent potliner prior to landfill disposal are provided. These methods, which involve treatment of the waste with a mixture containing an aqueous oxidizing solution and an agent, such as magnesium chloride, that increases the oxidation potential of the solution, can be performed at ambient temperature and pressure.Type: GrantFiled: June 23, 2000Date of Patent: July 22, 2003Assignee: Waste Management, Inc.Inventor: Gary Fisher
-
Patent number: 6576224Abstract: Pharmaceutical compositions are described that comprise one or more active ingredients selected from the group consisting of anti-infective, anti-inflammatory and mucolytic agents, and particularly to compositions formulated as a solution in a unit dose for aerosol administration to treat chronic sinusitis.Type: GrantFiled: May 25, 2000Date of Patent: June 10, 2003Assignee: SinusPharma, Inc.Inventors: Robert S. Osbakken, Mary Anne Hale, Frederick T. Leivo, James D. Munk
-
Patent number: 6545014Abstract: Methods, compositions, and compounds for modulating the activity of an endothelin peptide are provided. The methods use compositions that contain compounds that include those of the formula: where X is selected from groups that include O, S, and NH; Y is selected from O+ and N, and R1 and R2 are each selected independently from among alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, halide, pseudohalide or H, except that R2 is not halide. R3, R4 and R5 are selected from among groups that include hydrogen, halide, alkoxy, alkyl, haloalkyl; and R7 is selected from groups that include (CH2)rR18, in which r is 0 to 6 and R18 is selected from groups that include aryl, particularly pyrmidinyl and phenyl. The methods are effected by contacting endothelin receptors with one or more of the compounds or with compositions containing one or more of the compounds prior to, simultaneously with, or subsequent to contacting the receptors with an endothelin peptide.Type: GrantFiled: June 15, 2001Date of Patent: April 8, 2003Assignee: Texas Biotechnology CorporationInventor: Erik Joel Verner
-
Patent number: 6497341Abstract: A towel dispensing device provides a device for warming towels prior to the towels being removed from the dispensing device. The dispensing device includes an electrically powered heating member, the degree of heat being controllable by the user, for warming the space of a warming chamber containing the towels to be dispensed. The towels to be dispensed can be pre-moistened by water or other fluids as required by the user. The dispensing device can also be presented as a serialized group of warming chambers; each individual chamber being able to contain towels pre-moistened with different fluids and warmed to different temperatures prior to being dispensed.Type: GrantFiled: November 1, 2000Date of Patent: December 24, 2002Inventor: Gregg A. Motsenbocker
-
Patent number: 6432994Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.Type: GrantFiled: March 27, 2000Date of Patent: August 13, 2002Assignee: Texas Biotechnology CorporationInventors: Chengde Wu, Natalie Blok, Timothy Kogan, Karin Keller, Patricia Woodard
-
Patent number: 6420567Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.Type: GrantFiled: September 26, 1997Date of Patent: July 16, 2002Assignee: Texas Biotechnology CorporationInventors: Chengde Wu, Bore Gowda Raju, Timothy Kogan, Natalie Blok
-
Patent number: 6342610Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: November 7, 1997Date of Patent: January 29, 2002Assignee: Texas Biotechnology Corp.Inventors: Ming Fai Chan, Chengde Wu, Bore Gowda Raju, Timothy Kogan, Erik Joel Verner, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Adam Kois, Vitukudi Narayanaiyengar Balaji
-
Patent number: 6329387Abstract: Methods, compositions, and compounds for modulating the activity of an endothelin peptide are provided. The methods use compositions that contain compounds that include those of the formula: where X is selected from groups that include O, S, and NH; Y is selected from O+ and N, and R1 and R2 are each selected independently from among alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, halide, pseudohalide or H, except that R2 is not halide. R3, R4 and R5 are selected from among groups that include hydrogen, halide, alkoxy, alkyl, haloalkyl; and R7 is selected from groups that include (CH2)rR18, in which r is 0 to 6 and R18 is selected from groups that include aryl, particularly pyrimidinyl and phenyl. The methods are effected by contacting endothelin receptors with one or more of the compounds or with compositions containing one or more of the compounds prior to, simultaneously with, or subsequent to contacting the receptors with an endothelin peptide.Type: GrantFiled: November 17, 1999Date of Patent: December 11, 2001Assignee: Texas Biotechnology Corporation.Inventor: Erik Joel Verner